As previously reported, BofA analyst Jason Gerberry initiated coverage of Harmony Biosciences with a Neutral rating and $35 price target. While Harmony has "some likely favorable catalyst events in the near-term," this is balanced by consensus forecasts for narcolepsy drug Wakix that BofA sees as too high and having some downside risk. The firm is also more cautious on the drug’s loss of exclusivity being extended beyond 2028, the analyst noted.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony in ‘first innings of its valuation rebound,’ says Oppenheimer
- Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study
- Harmony short report ‘misleading,’ ‘perhaps even sensational,’ says Mizuho
- Raymond James says buy Harmony on weakness after ‘low quality’ short report
- Harmony Biosciences ‘disagrees’ with Scorpion Capital’s ‘assertions’
